Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$16.93 USD
+0.03 (0.18%)
Updated May 31, 2024 04:00 PM ET
After-Market: $16.92 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TEVA 16.93 +0.03(0.18%)
Will TEVA be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TEVA
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
Other News for TEVA
4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
Teva wins FDA nod for new Austedo formulation
Teva price target raised by $3 at BofA, here's why
Teva Pharmaceutical: A Strong Buy on Promising Biosimilar Prospects and Revenue Growth
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)